INNODIA
Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes
INNODIA assembles a comprehensive, complementary consortium of leading clinicians overseeing T1D registries and large clinical trial centres, aligned with basic science experts in beta-cell pathophysiology, immunology, biomarker discovery, bioinformatics, systems biology and trial design. INNODIA will accelerate understanding of T1D via coordinated studies of unique clinical samples and translation-oriented preclinical models delivering novel biomarkers and interventions for testing. Participants will be consented to recall, creating a ‘living biobank’.
In Norway we recruite first degree family members (aged 5-40 years) of patients with type 1 diabetes. First a blood test of autoantibodies is peformed and if positive prediabetes is diagnosed with a high risk for developing clinical type 1 diabetes. These participants undergo an organized follow-up and may be eligble for studies aiming to prevent clinical type 1 diabetes. Such prevention studies will start recruiting participants in the two years to come. Newly diagnosed patients are now enrolled in the DiViDInt Trial, which is affiliated to INNODIA.
Primary investigators:
Knut Dahl-Jørgensen
Torild Skrivarhaug
Geir Joner
Lars Krogvold
Co-investigators/participants:
Kristin Namtvedt Tuv, Consultant pediatrician, Sørlandet Hospital, Norway
Camilla Steinhovden, Study Nurse, Pediatric Dept. Oslo University Hospital
External collaborators:
INNODIA is a EU-IMI2-consortium with 40 partners: 31 academic institutions and clinics, 6 industrial partners and 2 patient organizations and one SME.
In fall 2020, 4 INNODIA clinical trials are launched and planned to be completed by 2022: MELD-ATG, IMPACT, VeR-A-T1D, CFZ533. The goal is to protect and strengthen the insulin producing beta cell in the pancreas. INNODIA is determined to find a way to stop the body´s immune attack from further destroying beta cells in newly diagnosed people with type one diabetes.